Premium
Interaction of α‐synuclein and tau genotypes in Parkinson's disease
Author(s) -
Mamah Catherine E.,
Lesnick Timothy G.,
Lincoln Sarah J.,
Strain Kari J.,
de Andrade Mariza,
Bower James H.,
Ahlskog J. Eric,
Rocca Walter A.,
Farrer Matthew J.,
Maraganore Demetrius M.
Publication year - 2005
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20387
Subject(s) - parkinson's disease , odds ratio , genotype , confidence interval , tau protein , disease , alpha synuclein , biology , medicine , genetics , oncology , neuroscience , psychology , gene , alzheimer's disease
To determine whether the microtubule‐associated protein tau (MAPT) and α‐synuclein (SNCA) genes interact to confer Parkinson's disease (PD) susceptibility, we conducted a study of 557 case–control pairs. There was an increased risk of PD for persons with either SNCA 261/261 or MAPT H1/H1 genotypes as compared with persons with neither (odds ratio, 1.96; 95% confidence interval, 1.34–2.86; p = 0.0003). However, the combined effect of the two genotypes was the same as for either of the genotypes alone (separate and equal). These findings are consistent with in vitro experiments that revealed tau‐mediated fibrillization of α‐synuclein protein at low concentrations (dose threshold effect). Ann Neurol 2005;57:439–443